Serotonin transporter polymorphisms in patients with portopulmonary hypertension

Kari E. Roberts, Michael B. Fallon, Michael Joseph Krowka, Raymond L. Benza, James A. Knowles, David B. Badesch, Robert S. Brown, Darren B. Taichman, James Trotter, Steven Zacks, Evelyn M. Horn, Steven M. Kawut

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The long allele of a functional promoter polymorphism in the serotonin transporter (SERT) is associated with an increased risk of some forms of pulmonary arterial hypertension. We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease. Methods: We performed a multicenter case-control study. Subjects undergoing liver transplant evaluation at seven centers were prospectively screened for the presence of PPHTN using transthoracic echocardiography. PPHTN was confirmed by right heart catheterization using standard criteria. Results: The study sample included 30 case patients with PPHTN and 109 control subjects with advanced liver disease. There was no significant association between the long allele and case status in an adjusted additive model (odds ratio, 0.63; 95% confidence interval, 0.33 to 1.21; p = 0.17). If anything, LL genotype tended to be associated with a lower risk of PPHTN. There were no associations between other SERT polymorphisms and PPHTN. Conclusions: SERT polymorphisms are not associated with the risk of PPHTN in patients with advanced liver disease. Other clinical or genetic risk factors may play a role in this complication of portal hypertension.

Original languageEnglish (US)
Pages (from-to)1470-1475
Number of pages6
JournalChest
Volume135
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Hypertension
Liver Diseases
Alleles
Portal Hypertension
Cardiac Catheterization
Pulmonary Hypertension
Echocardiography
Case-Control Studies
Odds Ratio
Genotype
Confidence Intervals
Transplants
Liver

Keywords

  • Cirrhosis
  • Gene polymorphism
  • Portal hypertension
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Roberts, K. E., Fallon, M. B., Krowka, M. J., Benza, R. L., Knowles, J. A., Badesch, D. B., ... Kawut, S. M. (2009). Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest, 135(6), 1470-1475. https://doi.org/10.1378/chest.08-1909

Serotonin transporter polymorphisms in patients with portopulmonary hypertension. / Roberts, Kari E.; Fallon, Michael B.; Krowka, Michael Joseph; Benza, Raymond L.; Knowles, James A.; Badesch, David B.; Brown, Robert S.; Taichman, Darren B.; Trotter, James; Zacks, Steven; Horn, Evelyn M.; Kawut, Steven M.

In: Chest, Vol. 135, No. 6, 01.06.2009, p. 1470-1475.

Research output: Contribution to journalArticle

Roberts, KE, Fallon, MB, Krowka, MJ, Benza, RL, Knowles, JA, Badesch, DB, Brown, RS, Taichman, DB, Trotter, J, Zacks, S, Horn, EM & Kawut, SM 2009, 'Serotonin transporter polymorphisms in patients with portopulmonary hypertension', Chest, vol. 135, no. 6, pp. 1470-1475. https://doi.org/10.1378/chest.08-1909
Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB et al. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest. 2009 Jun 1;135(6):1470-1475. https://doi.org/10.1378/chest.08-1909
Roberts, Kari E. ; Fallon, Michael B. ; Krowka, Michael Joseph ; Benza, Raymond L. ; Knowles, James A. ; Badesch, David B. ; Brown, Robert S. ; Taichman, Darren B. ; Trotter, James ; Zacks, Steven ; Horn, Evelyn M. ; Kawut, Steven M. / Serotonin transporter polymorphisms in patients with portopulmonary hypertension. In: Chest. 2009 ; Vol. 135, No. 6. pp. 1470-1475.
@article{1988748b4b39469d84b80712ddd25c17,
title = "Serotonin transporter polymorphisms in patients with portopulmonary hypertension",
abstract = "Background: The long allele of a functional promoter polymorphism in the serotonin transporter (SERT) is associated with an increased risk of some forms of pulmonary arterial hypertension. We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease. Methods: We performed a multicenter case-control study. Subjects undergoing liver transplant evaluation at seven centers were prospectively screened for the presence of PPHTN using transthoracic echocardiography. PPHTN was confirmed by right heart catheterization using standard criteria. Results: The study sample included 30 case patients with PPHTN and 109 control subjects with advanced liver disease. There was no significant association between the long allele and case status in an adjusted additive model (odds ratio, 0.63; 95{\%} confidence interval, 0.33 to 1.21; p = 0.17). If anything, LL genotype tended to be associated with a lower risk of PPHTN. There were no associations between other SERT polymorphisms and PPHTN. Conclusions: SERT polymorphisms are not associated with the risk of PPHTN in patients with advanced liver disease. Other clinical or genetic risk factors may play a role in this complication of portal hypertension.",
keywords = "Cirrhosis, Gene polymorphism, Portal hypertension, Pulmonary arterial hypertension",
author = "Roberts, {Kari E.} and Fallon, {Michael B.} and Krowka, {Michael Joseph} and Benza, {Raymond L.} and Knowles, {James A.} and Badesch, {David B.} and Brown, {Robert S.} and Taichman, {Darren B.} and James Trotter and Steven Zacks and Horn, {Evelyn M.} and Kawut, {Steven M.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1378/chest.08-1909",
language = "English (US)",
volume = "135",
pages = "1470--1475",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Serotonin transporter polymorphisms in patients with portopulmonary hypertension

AU - Roberts, Kari E.

AU - Fallon, Michael B.

AU - Krowka, Michael Joseph

AU - Benza, Raymond L.

AU - Knowles, James A.

AU - Badesch, David B.

AU - Brown, Robert S.

AU - Taichman, Darren B.

AU - Trotter, James

AU - Zacks, Steven

AU - Horn, Evelyn M.

AU - Kawut, Steven M.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Background: The long allele of a functional promoter polymorphism in the serotonin transporter (SERT) is associated with an increased risk of some forms of pulmonary arterial hypertension. We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease. Methods: We performed a multicenter case-control study. Subjects undergoing liver transplant evaluation at seven centers were prospectively screened for the presence of PPHTN using transthoracic echocardiography. PPHTN was confirmed by right heart catheterization using standard criteria. Results: The study sample included 30 case patients with PPHTN and 109 control subjects with advanced liver disease. There was no significant association between the long allele and case status in an adjusted additive model (odds ratio, 0.63; 95% confidence interval, 0.33 to 1.21; p = 0.17). If anything, LL genotype tended to be associated with a lower risk of PPHTN. There were no associations between other SERT polymorphisms and PPHTN. Conclusions: SERT polymorphisms are not associated with the risk of PPHTN in patients with advanced liver disease. Other clinical or genetic risk factors may play a role in this complication of portal hypertension.

AB - Background: The long allele of a functional promoter polymorphism in the serotonin transporter (SERT) is associated with an increased risk of some forms of pulmonary arterial hypertension. We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease. Methods: We performed a multicenter case-control study. Subjects undergoing liver transplant evaluation at seven centers were prospectively screened for the presence of PPHTN using transthoracic echocardiography. PPHTN was confirmed by right heart catheterization using standard criteria. Results: The study sample included 30 case patients with PPHTN and 109 control subjects with advanced liver disease. There was no significant association between the long allele and case status in an adjusted additive model (odds ratio, 0.63; 95% confidence interval, 0.33 to 1.21; p = 0.17). If anything, LL genotype tended to be associated with a lower risk of PPHTN. There were no associations between other SERT polymorphisms and PPHTN. Conclusions: SERT polymorphisms are not associated with the risk of PPHTN in patients with advanced liver disease. Other clinical or genetic risk factors may play a role in this complication of portal hypertension.

KW - Cirrhosis

KW - Gene polymorphism

KW - Portal hypertension

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=66149087952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149087952&partnerID=8YFLogxK

U2 - 10.1378/chest.08-1909

DO - 10.1378/chest.08-1909

M3 - Article

C2 - 19141529

AN - SCOPUS:66149087952

VL - 135

SP - 1470

EP - 1475

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -